TickerTalks
Browse all tickers →
TickerTalks›$LLY
LLLLY

Eli Lilly and Company

Strong FundamentalsStrong FundamentalsRevenue growing 56% YoY at strong marginsStreet coverage with positive forward estimatesConsistent chatter on X (875/wk), no spike
$LLY·$1.1T·Drug Manufacturers - General·Healthcare
$1180.16-2.4%YTD+3.7%1Y+72.4%
Mentions · last 7 days
2026-08-07: 129 posts2026-08-08: 53 posts2026-08-09: 71 posts2026-08-10: 162 posts2026-08-11: 144 posts2026-08-12: 169 posts2026-08-13: 138 posts875-56%
Price updated 1d ago·X counts updated 2d ago
LLLLY
$LLYEli Lilly and Company
$1,180.16-2.39%875 posts-56%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $LLY, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersCooling offAI verdict · as of 2026-08-15

Catching its breath after a run — could pick back up or fade from here.

Lilly is the GLP-1 category leader with a $1T market cap — Zepbound is still winning the obesity fight, but two officer sales this week nudge caution.

Eli Lilly is a large-cap pharma anchored on Zepbound (the tirzepatide obesity drug) and Mounjaro (diabetes) — the two products that made LLY the world's most valuable pharma company. The story now is defending category leadership vs Novo Nordisk while the pipeline (retatrutide, oral GLP-1s) works toward the next generation.

  • Growth is exceptional at scale: Q1 revenue of $19.8B grew 56% YoY with 82% gross margins and 45% operating margins — that combination in pharma at $1T market cap is genuinely rare.
  • Q2 was another beat: EPS of $8.38 vs $6.40 estimate (+31%) with revenue of $23B — the fourth consecutive beat and guidance was raised, so consensus is still trailing demand.
  • The moat looks intact: Zepbound leads physician satisfaction 80% vs Wegovy 59%, six lawsuits vs retatrutide grey-market sellers, and UK approved Foundayo (first in Europe).
  • Insider tape has a caveat: CLO Hakim sold $5.95M at $1,190 on 8/7 and controller Zakrowski sold $2.37M at $1,185 on 8/11 — meaningful, though small vs $1T cap.
  • Position at 88% of 52-week range but only +0.9% vs the 50-day — a run consolidated near highs, not extending, with volume below normal.

October 29 is the next test — a fifth consecutive beat with Zepbound scripts still growing 20%+ QoQ extends the compounding story; any Novo competitive push (new-formulation launch, price move) or supply-constraint disclosure is the invalidator. Rare-mention risk: a genuine oral-GLP-1 clinical failure would reset the multi-year story.

Agrees with X sentimentAgrees with the X bulls that LLY is still the obesity category leader — the 80% vs 59% physician-satisfaction data and Q2 revenue growth back that up. Partial agreement only because the two officer sales this week ($8.3M combined) are the kind of tell that's worth weighting alongside the technical breakout narrative.

What to watch: October 29 Q3 earnings — Zepbound script growth and any Novo competitive-response commentary. A fifth consecutive beat plus 20%+ Zepbound QoQ extends the run; any supply constraint or Novo new-formulation launch is the invalidator.

On the calendar: 2026-10-29 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment96 posts analyzed · as of 2026-08-14

Eli Lilly's timeline is bullish. Posters cite the Q2 print with 31% EPS beat and raised guidance, a cup breakout followed by a tight flat base, UK approving Foundayo (first in Europe), and Lilly's six new lawsuits against retatrutide grey-market sellers as evidence of aggressive brand defense. Zepbound continues to lead physician satisfaction in obesity (80% vs Wegovy's 59%). A rare measured voice notes there was no volume behind the breakout so this trader passed. Overall the dominant read is 'LLY is the winner in obesity for now.'

Read the AI verdict + X sentiment for $LLY

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes GLP-1 drugs Mounjaro and Zepbound for diabetes and obesity, plus Kisunla for Alzheimer's, with massive manufacturing expansion.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $LLY.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $LLY

Partial — Makes GLP-1 drugs Mounjaro and Zepbound for diabetes and obesity, plus Kisunla for Alzheimer's, with massive manufacturing expansion; partial earnings exposure to drug manufacturers - general demand dynamics through its product portfolio.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+48.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
40.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
32.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
45.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
14.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
101%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
83.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$8.38$6.40+30.9%
Q1 2026Apr 30, 2026$8.55$6.97+22.7%
Q4 2025Feb 4, 2026$7.54$6.91+9.1%
Q3 2025Oct 30, 2025$7.02$5.69+23.4%
Next earningsThu, Oct 29·consensus EPS $9.71

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$19.8B+55.5%81.9%44.7%$8.27$3.0B
Q4 FY25$19.3B+42.6%85.1%45.5%$7.41$677.9M
Q3 FY25$17.6B+53.9%82.9%47.6%$6.22$8.6B
Q2 FY25$15.6B+37.6%84.3%45.8%$6.30$1.3B

Forward consensus

5-year forecast · up to 22 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$85.3B$83.1B – $88.3B$35.04$32.65 – $37.3418
FY27$99.3B$94.0B – $101.8B$45.18$40.58 – $47.4818
FY28$111.3B$100.1B – $126.9B$52.15$46.24 – $59.0622
FY29$121.5B$114.1B – $130.4B$58.67$54.07 – $64.2715
FY30$131.5B$123.6B – $141.1B$64.76$59.68 – $70.9311

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.88%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+13.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 848.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.515-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 10Donald A ZakrowskiSVP, Finance, & CAO2.0K sh$2.4MSellAug 7Anat HakimEVP, GC & Secretary5.0K sh$6.0MSellJun 10Ilya YuffaEVP&Pres, LLY USA&Global Capab2.5K sh$2.9MSellMay 6Lilly Endowment IncFormer 10% Shareholder15.8K sh$15.8M
+ 27 other (24 awards · 1 exempt · 1 inkind · 1 gift) in window

See when $LLY insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13DActivist position (5%+)Jul 30SC 13D
AI summary

Eli Lilly and Company (LLY) filed a Schedule 13D for Scribe Therapeutics, Inc. (SCTX) disclosing beneficial ownership of 1,388,161 shares equal to approximately 7.3% of post-IPO outstanding shares (calculated based on 18,864,386 shares outstanding after IPO including overallotment). The stake was acquired using Lilly's working capital following SCTX's IPO on or around July 27, 2026. Lilly's 7.3% strategic position in SCTX — a CRISPR gene editing company co-founded by Jennifer Doudna — signals a strategic interest in Scribe's base-editing technology platform, potentially a precursor to a licensing or acquisition.

3New insider — initial holdingsJul 233
AI summary

ELI LILLY & Co filed a Form 3 (initial statement of beneficial ownership) for Scribe Therapeutics, Inc. (SCTX), with 1,054,828 shares beneficially owned. Filer's relationship to issuer: Director, President, 10%+ Owner. This represents a significant beneficial ownership position. Form 3 must be filed within 10 days of becoming a new 10%+ owner or executive/director. This is an administrative ownership disclosure — no open-market transaction has occurred.

8-KShareholder voteMay 78-K — Item 5.07: Shareholder vote
AI summary

LLY held its annual meeting of stockholders around 2026-05-07 (8-K Item 5.07). Stockholders elected 2 directors to the board. Routine governance event — monitor for unusually high withhold votes as an activist signal.

+ 19 other (6 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Bank of America Sees Bargains in These 16 Knocked-Down AI Stocksinvestopedia.com·1d ago3 Large-Cap Stocks to Watch as Pharma Recovery Takes Holdzacks.com·2d agoFidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?fool.com·2d agoSimplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now?fool.com·2d agoNovo CEO says obesity market won't be winner-take-all battle with Lillyreuters.com·3d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NVO$PFE$JNJ$MRK$ABBV$BMY$ZTS$GILD
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport